Ovoca Bio PLC Result of AGM (9766G)
29 Julho 2021 - 1:00PM
UK Regulatory
TIDMOVB
RNS Number : 9766G
Ovoca Bio PLC
29 July 2021
Ovoca Bio plc
("Ovoca" or the "Company")
Results of AGM
Dublin, Ireland, July 29, 2021 - Ovoca Bio, a biopharmaceutical
company with a focus on women's health, announces that earlier
today it held its Annual General Meeting.
All resolutions proposed at the Annual General Meeting were
passed. Voting on all resolutions was conducted by poll and the
results are available on the Company's website at www.ovocabio.com
.
The full text of the approved resolutions can be found in the
Notice of the Annual General Meeting. The Notice is also available
to view and download from the Company's website.
End
For further information:
Ovoca Bio plc
Kirill Golovanov (Chief Executive)
Tel +353 1 661 9819
info@ovocabio.com
Davy (Nominated Adviser, Euronext Growth Advisor and Broker)
John Frain / Daragh O'Reilly
Tel: +353 1 679 6363
Consilium Strategic Communications
Chris Gardner, Chris Welsh, Carina Jurs
ovocabio@consilium-comms.com
Tel: +44 (0)20 3709 5700
About Ovoca Bio
Ovoca Bio is a European-based biopharmaceutical company with a
focus on women's health. The Company is currently developing a
novel treatment for women with hypoactive sexual desire disorder
(HSDD).
The Company's lead product, BP-101, a novel synthetic peptide
administered through a nasal spray, is clinically validated, with
Phase II and Phase III studies conducted in Russia demonstrating
statistically significant improvement in a number of key efficacy
outcomes, including an increase in female sexual desire and
reduction of symptoms of distress associated with HSDD.
Ovoca Bio is seeking to develop the drug for major global
markets - in particular the United States and Europe, as well as
obtain marketing approval in the Russian Federation.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
RAGBUGDRXSDDGBC
(END) Dow Jones Newswires
July 29, 2021 12:00 ET (16:00 GMT)
Ovoca Bio (AQSE:OVB.GB)
Gráfico Histórico do Ativo
De Dez 2024 até Jan 2025
Ovoca Bio (AQSE:OVB.GB)
Gráfico Histórico do Ativo
De Jan 2024 até Jan 2025
